

Estrogen Receptor β Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts

Johan Hartman,¹ Karolina Lindberg,¹ Andrea Morani,² José Inzunza,² Anders Ström,¹ and Jan-Åke Gustafsson^{1,2}

¹Center for Biotechnology and ²Division of Medical Nutrition, Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden

Abstract

Estrogens, which are stimulators of growth of both the normal breast and malignant breast, mediate their effects through two estrogen receptors (ER), namely ER α and ER β . ER α mediates the proliferative effect of estrogen in breast cancer cells, whereas ER β seems to be antiproliferative. We engineered ER α -positive T47D breast cancer cells to express ER β in a Tet-Off-regulated manner. These cells were then injected orthotopically into severe combined immunodeficient mice, and the growth of the resulting tumors was compared with tumors resulting from injecting the parental T47D cells that do not express ER β . The presence of ER β resulted in a reduction in tumor growth. Comparison of the ER β -expressing and non-ER β -expressing tumors revealed that the expression of ER β caused a reduction in the number of intratumoral blood vessels and a decrease in expression of the proangiogenic factors vascular endothelial growth factor (VEGF) and platelet-derived growth factor β (PDGF β). In cell culture, with the Tet-Off-regulated ER β -expressing cells, expression of ER β decreased expression of VEGF and PDGF β mRNA under normoxic as well as hypoxic conditions and reduced secreted VEGF and PDGF β proteins in cell culture medium. Transient transfection assays with 1,026 bp VEGF and 1,006 bp PDGF β promoter constructs revealed a repressive effect of ER β at the promoter level of these genes. Taken together, these data show that introduction of ER β into malignant cells inhibits their growth and prevents tumor expansion by inhibiting angiogenesis. (Cancer Res 2006; 66(23): 11207-13)

Introduction

Breast cancer is one of the leading forms of cancer in the Western world. It is well documented that the mitogenic actions of estradiol (E₂) are critical in the etiology and progression of human breast cancers (1). For this reason, patients with estrogen receptor α (ER α)-positive tumors are treated with tamoxifen, which blocks the action of ER α , or with aromatase inhibitors, which block the synthesis of E₂ (2–4). These treatments are effective but patients inevitably develop hormone-resistant, invasive tumors. Because ER β is expressed in the normal breast, it is pertinent to ask whether this receptor might also be used as pharmacologic target in the treatment of breast cancer.

Note: Possible conflict of interest: J-Å. Gustafsson is cofounder, deputy board member, consultant, and shareholder of KaroBio AB.

Requests for reprints: Johan Hartman, Center for Biotechnology, Department of Biosciences and Nutrition, Karolinska Institutet, Novum, S-141 57 Huddinge, Sweden. Phone: 46-86089150; Fax: 46-87745538; E-mail: johan.hartman@biosci.ki.se.

©2006 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-06-0017

In breast cancer cells as well as in various mouse models, estrogens via ER α stimulate proliferation and inhibit apoptosis (5, 6), whereas ER β opposes the proliferative effect of ER α *in vitro* (7, 8). Several studies have reported that during tumor development in the breast epithelium, the expression of ER α increases, whereas that of ER β decreases (9, 10). For a tumor to grow, increased proliferation must be accompanied by increased blood supply and this is achieved by angiogenesis and increased blood microvessel density (11–13). Angiogenesis is an essential process in normal tissue growth and repair and is regulated by multiple factors, including supply of nutrients, vascular endothelial growth factor (VEGF), platelet-derived growth factor β (PDGF β), basic fibroblast growth factor (bFGF), and oxygen tension. Estrogens are important stimulators of angiogenesis in health as well as disease. In the uterine endometrium, estrogens via ER α increase the transcription of VEGF (14, 15) and stimulate angiogenesis. Tamoxifen is antiangiogenic (16, 17).

The question addressed in the present study is whether an established breast cancer cell, which does not express ER β , can be influenced to behave more like a normal cell upon reintroduction of ER β . To answer this question, we engineered T47D breast cancer cells with a tetracycline-regulated ER β expression vector. We show here that both proliferation of the cancer cell and its ability to grow as a solid tumor in severe combined immunodeficient (SCID) mice were reduced upon expression of ER β .

Materials and Methods

Stable cell lines and cell cultures. T47D cells were grown in DMEM/Ham's F-12 (1:1) (Invitrogen) supplemented with 5% fetal bovine serum (FBS). T47D cells stably transfected with tetracycline-regulated ER β expression plasmid were generated in two steps. The cells were first transfected with pTet-tTak (Life Technologies) modified to contain puromycin resistance using Lipofectamine according to instructions of the manufacturer (Life Technologies). Selection was done with 0.5 μ g/mL puromycin in the presence of 1 μ g/mL tetracycline. A clone showing high levels of induction upon tetracycline withdrawal and low basal activity was selected by using the pUHC13-3 control plasmid (Life Technologies). The short form of ER β encoding the COOH-terminal 485 amino acids [the reason why the long form of ER β (530 amino acids) was not used was that it was lethal to the cells] was fused to the FLAG tag (ER β 485) and cloned into pBI-EGFP (Clontech). This construct was then transfected into the previously described inducible cell clone together with a neomycin resistance plasmid, and selection was done with 500 μ g/mL G418 (Calbiochem), 1% penicillin-streptomycin (Invitrogen), and 0.1% kanamycin (Sigma, St. Louis, MO). For experimental conditions, stripped medium was used, i.e., phenol red-free medium (Invitrogen) supplemented with dextran/charcoal-treated FBS. E₂ (Sigma) was dissolved in ethanol and 40H-tamoxifen (Sigma) was dissolved in DMSO.

Experimental animals and xenograft model. Cells from one confluent 150-cm² Falcon cell culture flask per mouse with T47D-ER β or normal T47D cells of the same clonal origin was diluted with 200 μ L normal medium + 200 μ L Matrigel (BD Falcon, San Jose, CA). The cell suspension

was injected into the mammary fat pad of 5-week-old pathogen-free SCID/beige mice (Taconic, Ry) on day 0. E₂ pellets, 0.72 mg/pellet (IRA, Sarasota, FL), were injected s.c. in the neck with pellet trochar (IRA). After 4, 8, 16, or 30 days, the mice were sacrificed and the tumor volume was measured with caliper according to the formula length × width × height. All tumors were fixed in 4% paraformaldehyde and stored in 75% ethanol. After this, tissue was paraffin-embedded and subsequently sliced into 4.5-μm sections according to standard protocol. Tumors of sufficient size at necropsy were divided into three similar parts for preparation of mRNA and protein as described below.

Western immunoblotting. Cells were plated and grown in 150-mm plates until 30% confluence was reached. At time point 0, the cells were incubated with E₂ with or without tetracycline. Harvesting and extraction were done at different times (0-36 hours) according to standard protocol. SDS-PAGE was done as described (18). The following primary antibodies were used: VEGF (Santa Cruz Biotechnology, Santa Cruz, CA), PDGFβ (BD Biosciences, San Jose, CA), Ki67 (DakoCytomation, Carpinteria, CA), CD31 (BD Pharmingen, San Diego, CA), β-actin (Sigma), and ERβ (chicken antibody raised in our laboratory).

Immunohistochemistry. Antigen retrieval was done by microwave boiling in 0.01 mol/L citric acid (pH 6.0) or with Proteinase K solution for CD31 staining. Endogenous peroxidase activity was blocked with 0.5% hydrogen peroxide. Primary antibody was diluted 1:100 to 1:500 in 3% bovine serum albumin and 0.3% Triton X-100 (see above for antibody specifications) and incubated overnight at 4°C, followed by incubation with a biotinylated secondary antibody (1:200) in 0.3% Triton X-100 for 1 hour. Biotinylated secondary antibodies used were anti-mouse IgG and anti-rat IgG, both from Vector Laboratories (Burlingame, CA), incubated (1:200) in 0.3% Triton X-100 for 1 hour. Sections were finally incubated in the streptavidin-horseradish peroxidase ABC complex (Vector Laboratories) for 1 hour, stained in 3,3'-diaminobenzidine, and counterstained with Mayer hematoxylin (Sigma, Poole, United Kingdom) before dehydration through ethanol, and mounted in dibutyl phthalate xylene.

Measurement of microvessel density and counting of Ki67- and ERβ-positive cells. Microvessel density was calculated by first identifying the areas of highest vascularization with ×10 objective in the periphery of CD31 immunohistochemically stained tumor slides. Microvessel density was then determined by counting the number of vessels with ×20 objective in two independent fields per tumor. Vessels to be counted were identified by one of the following criteria: CD31 (mouse)-positive vascular formations or vascular formations containing luminal erythrocytes. Average microvessel density and SD of each group (±ERβ) was measured. Counting of ERβ/Ki67-positive cells on immunohistochemically stained slides was done by first identifying areas with most intensive staining. The number of Ki67- and ERβ-positive cells in two independent fields per tumor slide was counted with ×20 objective. Average number of stained cells and SD for each group (±ERβ) were calculated.

ELISA assay. ERβ-inducible T47D cells were incubated in estrogen-depleted RPMI medium containing 50 nmol/L ICI for 48 hours. Thereafter, medium was changed to normal RPMI medium ± E₂, ±tetracycline, and cell cultures were placed in hypoxia chamber containing <1% O₂ at 37°C. After 72 hours, the conditioned cell medium was analyzed according to standard ELISA protocol (Quantakine human VEGF and PDGFβ; R&D Systems, Minneapolis, MN). RNA was extracted and purified from the T47D cells according to standard protocol.

Real-time PCR. RNA extraction and cDNA synthesis were done as described earlier (19). Real-time PCR was done with SYBR-Green PCR Master Mix or TaqMan Universal Mastermix (Applied Biosystems, Foster City, CA). The following primers and probes were used: *VEGF* forward: 5'-CTC-TACCTCCACCATGCCAAGT-3'; reverse: 5'-TGATTCTGCCCTCCTC-CTTCT-3'. *PDGFβ* forward: 5'-CTGCTACCTGCGTCTGGTCA-3'; reverse: 5'-CATCAAAGGAGCGGATCGA-3. *ERβ* forward: 5'-TCCATGCGCCTGGC-TAAC-3'; reverse: 5'-CAGATGTCCATGCCCTTGTA-3. Probe: 5'-FAM (6-carboxyfluorescein)-TCCTGATGCTCTCTGCCACGTCA(6-carboxytetramethylrhodamine)-3'. *18S rRNA* forward: 5'-CCTGCGGCTTAATTTGACTCA-3'; reverse: 5'-AGCTATCAATCTGTCAATCCTGTCC-3 as a reference gene. The real-time PCR reactions were done in an ABI PRISM 7500 (Applied

Biosystems) under the following conditions: 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 to 50 cycles at 95°C for 15 seconds and 60°C for 1 minute. The optimum concentration of primers was determined in preliminary experiments and all primer pairs were checked with melting curve analysis.

Cloning and transfections. The *VEGF* promoter (forward primer, 5'-AAATCTTCTCCCTGGGAA-3'; reverse primer, 5'-AATGAATATCAAA-TTCCAGCA-3') and *PDGFβ* promoter (forward primer, 5'-CAGTGCAAGCG-GAGGAGATGA-3'; reverse primer, 5'-CGGCTGCAGGAGAGAAGTTG-3') were amplified by PCR from human genomic DNA and subsequently subcloned into pGL3-basic luciferase vector (Promega).

Transfection of T47D cells was done by culturing cells on six-well cell culture dishes until 50% to 70% confluence was reached, whereupon the cells were synchronized. Transient transfections were done using Lipofectamine 2000 (Invitrogen) according to the protocol from the manufacturer. The reporter plasmid (*VEGF* or *PDGFβ* promoter 1.0 μg/well) was transiently cotransfected together with an expression plasmid (*ERβ* 0.5-0.1 μg) for 6 hours. When necessary, the total amount of DNA was completed with pcDNA3 (Invitrogen). After transfection, cells were treated with 10 nmol/L E₂ or ethanol in stripped medium for 24 or 48 hours. Cells were then lysed and luciferase activity was determined with a microplate luminometer (Berthold) using luciferase assay kit from Biothema. All data were normalized to β-galactosidase enzyme activity obtained after cotransfection with a β-galactosidase-lacZ plasmid (100 ng/well).

Hypoxia chamber experiments. T47D-ERβ cells were incubated for 48 hours in normal stripped medium without E₂ during normoxia. Cells were then incubated in 0.5% O₂ in 37°C for 48 hours in the presence of E₂. Cells were subsequently harvested with TRIzol reagent according to instructions from the manufacturer.


Statistics. Values are expressed as means with 95% confidence intervals. Tumor growth curves were constructed from the mean tumor volume at each time point of measurement. Unpaired, two-tailed *t* test was used to compare differences between two groups. One-way ANOVA analysis with Tukey's multiple comparison posttest was used to test differences between three or more groups. Significance is presented as **P* < 0.05; ***P* < 0.005; ****P* < 0.001; and NS, nonsignificant.

Results

Expression of ERβ reduces volume of T47D breast cancer xenografts. In ERα-positive breast cancer cells such as T47D or MCF7, E₂ treatment leads to increased proliferation and increased tumor growth when these cells are implanted into mice (20, 21). To study the effect of ERβ in this context, we have generated T47D breast cancer cells with stable Tet-Off-inducible ERβ expression. These cells are grown in the presence of tetracycline and should only express high levels of ERβ after removal of tetracycline. By orthotopic implantation of T47D-ERβ or parental T47D cells into SCID/beige mice, the effect of ERβ on ERα-induced tumor growth may be investigated. Preliminary studies with T47D-ERβ cells implanted into SCID/beige mice showed that there was some expression of ERβ even in the presence of tetracycline. Accordingly, tumor growth in the presence of tetracycline could not be used as baseline measure of ERα-controlled growth and parental T47D cells were used instead. T47D cells are E₂ dependent for their growth; therefore, at the start of the experiment, all animals were implanted with 60-day-release E₂ pellets. To confirm that ERβ was expressed in T47D-ERβ tumors, ERβ mRNA and protein levels were monitored by real-time PCR and immunohistochemical analysis. There was an extremely low, but nonetheless measurable, level of ERβ mRNA in T47D cells.

As shown in Fig. 1A, exogenous ERβ expression reduced tumor volume at end point 30 days by 80%. Of the eight mice implanted with T47D-ERβ, in three animals at necropsy, no tumor tissue could be found. Thirty days after implantation, levels of ERβ

Figure 1. SCID/beige mice orthotopically transplanted with Tet-Off ER β -inducible T47D cells or normal T47D cells as control. Both cells were of identical clonal origin. Mice were subsequently implanted with slow-release E₂ pellet. **A**, tumor volume of removed xenografts at end point 30 days. **Control column**, normal T47D xenograft ($n = 6$); **+ER β column**, ER β -overexpressing xenografts ($n = 8$). **Columns**, average volumes; **bars**, SD ($P = 0.0003$). **B**, ER β -mRNA levels in the tumor xenografts above. **Columns**, average ($n = 6, 3$); **bars**, SD ($P = 0.0004$). **C**, Number of ER β -positive and **D**) Ki67-positive cells in xenograft slides per visual field ($\times 20$ objective) identified by immunohistochemistry. **Column 1**, ER β -expressing xenografts from mice sacrificed 4 days after implantation ($n = 4$); **columns 2, 3, and 4**, xenografts 8 ($n = 4$), 16 ($n = 4$), and 30 days ($n = 6$) after implantation; **column 5**, T47D control xenografts ($P = 0.0421$ in **C**). Number of positive cells was counted in the two most intensively stained areas on each xenograft slide. **Columns**, average; **bars**, SD. Significance is presented as *, $P < 0.05$; ***, $P < 0.001$.




mRNA in T47D-ER β xenografts were >10-fold higher than in the T47D xenografts (Fig. 1B). Immunohistochemical detection of ER β in paraffin-embedded tumor slides showed strong expression of ER β 4 to 16 days after implantation. There was a gradual decline in expression so that by day 30, there was only a small but statistically significant difference in ER β expression between the T47D-ER β and the T47D tumors ($P = 0.0421$; Fig. 1C).

As expected, the Ki67 proliferation index was decreased in the ER β -expressing tumors, and at all time points Ki67 was inversely

associated with ER β expression (Fig. 1D). As the number of ER β -expressing cells decreased after day 16, the number of Ki67-positive cells increased. Representative pictures of ER β and Ki67 immunohistochemically stained slides are shown in Fig. 2.

ER β expression correlates to reduced microvessel density. The supply of oxygen and nutrients provided by angiogenesis is necessary for tumor growth, and the microvessel density is a strong predictor of aggressive disease (13). To investigate whether ER β influenced angiogenesis in the tumors, endothelial cells were

Figure 2. Representative pictures of (A) ER β and (B) Ki67 immunohistochemically stained slides from the xenografts analyzed in Fig. 1C and D.



visualized with an antibody against mouse CD31. These immunohistochemical studies revealed that ER β expression correlated significantly to reduced microvessel density (Fig. 3A).

Angiogenesis is dependent on growth factors and their receptors. The most important factors in tumor angiogenesis are VEGF, bFGF, PDGF β , and angiopoietins (22, 23). These factors are also up-regulated in high-stage and high-grade human tumors (24). Therefore, we investigated the expression of these factors in the T47D-ER β and T47D xenografts. By Western blot analysis of tumor lysates, we found that the total amount of VEGF and PDGF β proteins was decreased in the ER β -expressing tumors (Fig. 3B). Due to the very small volume of the ER β -expressing tumors, proteins could not be extracted from all tumors. Real-time PCR analysis of tumor xenografts from 30 days \pm ER β expression showed no significant difference in VEGF mRNA but a strong inhibition of PDGF β -mRNA by ER β expression ($P = 0.003$; Fig. 3C). In Fig. 3D, representative immunohistochemical pictures are shown.

ER β decreases expression of VEGF and PDGF β in T47D-ER β cells. We investigated whether ER β was directly involved in regulating the production of VEGF and PDGF β or whether the

induction of these factors was induced by hypoxia independent of the presence of ER β . We incubated ER β -inducible T47D cells *in vitro* under normoxic conditions (20% O $_2$) in presence of E $_2$. Expression of ER β reduced VEGF mRNA as well as in secreted form under both normoxic and hypoxic conditions (Fig. 4A and B). PDGF β was strongly down-regulated at the mRNA level and at secreted protein level as a result of ER β expression, both under normoxic and hypoxic conditions (Fig. 4C and D). To further investigate this transcriptional regulation, cells were transiently transfected with promoter constructs of VEGF and PDGF β . E $_2$ treatment resulted in an increase in promoter activity with both constructs (Fig. 5), caused by ligand activation of ER α . Cotransfection of an ER β expression vector resulted in reduction of VEGF and PDGF β promoter activities in the presence of E $_2$.

Discussion

We have previously shown that expression of ER β in cultures of T47D cells opposes ER α -mediated cell cycle progression by interference with cell cycle factors such as cyclin E and Cdk2 (7).





Figure 3. Inhibition of tumor angiogenesis by ER β expression at 30 days.

A, microvessel density (MVD) in control T47D xenografts ($n = 6$) and ER β -overexpressing xenografts ($n = 5$). Animals were sacrificed at end point 30 days. Microvessel density was measured as the number of CD31-positive vessels per visual field ($\times 20$ objective) identified by immunohistochemistry of xenografts. Number of vessels were counted in the two most intensively stained areas on each xenograft slide. Columns, average; bars, SD ($P < 0.0001$). Lysates from these xenografts showing average (B-1) VEGF ($n = 6, 3; P = 0.0723$) and (B-2) PDGF β protein levels ($n = 6, 3; P = 0.006$). Columns, average; bars, SD. Lysates were analyzed by absorbance of Western blot membranes (Bio-Rad software). Data were based on VEGF or PDGF β / β -actin density of each sample with representative Western blot. mRNA expression of VEGF (C-1; $n = 6, 3; P = 0.34$) and PDGF β (C-2; $n = 6, 3; P = 0.003$) in tumor xenografts, analyzed with real-time PCR. Columns, average; bars, SD. Representative immunohistochemical pictures of control xenograft (D-1) and ER β -overexpressing xenograft (D-2) analyzed in (A). Arrows in D-1, CD31-stained endothelium. Significance is presented as **, $P < 0.005$; ***, $P < 0.001$; NS, non-significant differences.

Figure 4. Inhibition of growth factor expression *in vitro*. mRNA expression in ER β -inducible T47D breast cancer cells incubated with E₂ \pm hypoxia (<1% O₂) \pm tetracycline for 24 hours, and protein levels in cell culture medium after 72 hours incubation with E₂ + hypoxia (<1% O₂) were analyzed with ELISA assay. **A**, VEGF mRNA ($P = 0.0232$, columns 3-4). **B**, VEGF protein level ($P < 0.0001$) in cell culture medium, **(C)** PDGF β mRNA ($P = 0.0028$, columns 3-4), and **(D)** PDGF β protein level ($P = 0.0048$) in cell culture medium. Columns (A and C), average of triplicates; (B and D), average of at least two independent experiments; bars, SD. Significance is presented as *, $P < 0.05$; **, $P < 0.005$.



The purpose of the present study was to determine whether the observations made in cell culture would apply to breast cancer cells *in vivo*. As shown by others using viral transfection systems, ER β inhibits tumor formation of MCF-7 cells in a mouse model (8). One critique of viral transfection studies is that uncontrolled overexpression of the transfected gene leads to unphysiologically high protein levels. With the use of a Tet-Off-system, we here report that when ER β expression is induced in breast cancer xenografts, tumor growth is inhibited. Furthermore, the proliferation marker Ki67 was inversely associated with ER β in most groups; when the number of ER β + cells was high, the number of Ki67+ cells was low, whereas when the number of ER β + cells was low, the number of Ki67+ cells was high (Fig. 1C and D). This finding gives further support to the notion that ER β is antiproliferative.

There was a decrease in the number of ER β + tumor cells from days 16 to 30 in the T47D-ER β group (Fig. 1C), in spite of strong induction of ER β at mRNA level. The reason for this loss is not known but a possible mechanism could be increased ER β protein degradation. This would also be in line with the reports showing decreased ER β levels in breast cancer. Studies of the mechanisms behind the observed decrease in ER β levels in the transplanted tumor cells are ongoing.

One possible explanation for the reduction in tumor volume by ER β expression could be the influence of ER β on angiogenesis. We found that in the T47D-ER β xenografts, microvessel density was significantly lower than in the parental T47D tumors (Fig. 3A). As expected, PDGF β was reduced on both mRNA and protein level in the T47D-ER β xenografts. We could see no

reduction of VEGF-mRNA in xenografts by ER β expression but a nonsignificant trend toward a reduction of VEGF protein ($P = 0.0723$; Fig. 3B and C).

Tamoxifen, which is known to activate ER β in certain promoter contexts, has been shown to inhibit growth of breast cancer xenografts by affecting angiogenesis (25). Because oxygen tension is a major stimulator of angiogenesis, the question was whether the lower microvessel density in the ER β -expressing tumors was simply because the tumors were smaller and less hypoxic. We therefore analyzed the expression of the three most important proangiogenic factors, namely VEGF, bFGF, and PDGF β , during normoxic as well as hypoxic conditions *in vitro*.

Secreted bFGF protein was not detectable in the cell culture supernatants but both PDGF β and VEGF were reduced by ER β expression (Fig. 4).

It has earlier been reported that ER α increases the expression of PDGF β , bFGF, and VEGF, and that this induction of growth factors might be an important mechanism explaining how ER α stimulates breast cancer growth and progression. The role of ER β in regulation of PDGF β is not clear; furthermore, there are conflicting data as to how ER β affects VEGF expression in tumors (26, 27).

In transient transfections with a 1,026 bp VEGF promoter construct, a reduction in promoter activity by cotransfection with ER β was seen in the presence of E₂. Accordingly, ER β might be a direct transcriptional inhibitor of VEGF, opposing the effect of ER α . E₂ treatment in the absence of ER β cotransfection showed only a minor up-regulation of the VEGF promoter activity. Earlier reports with longer promoter constructs have shown strong




Figure 5. Transient transfections of T47D cells with (A) pGL3-VEGF-LUC (-881/+145; $P = 0.0211$, columns 2-4) and (B) pGL3-PDGFB-LUC (-981/+25; $P = 0.0096$, columns 2-4) \pm cotransfection with ER β expression vector \pm E $_2$. All data were normalized to β -galactosidase enzyme activity obtained after cotransfection with a β -galactosidase-lacZ plasmid. Columns, average of triplicates; bars, SD. All experiments were repeated with similar results. Significance is presented as *, $P < 0.05$; **, $P < 0.005$.

activation by ER α (28). VEGF is well known for its activation of endothelial cells, resulting in their proliferation and migration. In addition, as shown in a recent report (29), VEGF influences breast cancer cell survival and growth by direct effects on cancer cell surface VEGFR-2 in an autocrine fashion.

Transient transfections with 1,006 bp PDGF β promoter constructs also showed inhibition by ER β . PDGF β is a growth factor with wide potentials. In addition to its proangiogenic effects, PDGF family members stimulate proliferation of breast cancer cells (30). Also, PDGF β have been reported to induce aromatase activity in T47D cells (31). Therefore, it is an interesting possibility that induction of ER β would actually inhibit the local production of E $_2$ in breast tumors, in the same way as pharmaceutical aromatase inhibitors do. Reduction of growth factor expression could provide one explanation as to how ER β inhibits tumor growth. Furthermore, preliminary experiments done by our group indicate that ER β correlates inversely to PDGF β and VEGF mRNA in purified breast cancer cells from 14 different human breast tumors. This will be investigated in more detail with increased sample size.

Altogether, our results indicate an antitumorogenic role of ER β in breast cancer. This makes ER β an interesting therapeutic target in breast cancer and perhaps treatment with ER β -selective ligands might work as both antiproliferative and antiangiogenic therapy.

Acknowledgments

Received 1/4/2006; revised 9/17/2006; accepted 10/3/2006.

Grant support: Swedish Cancer Fund, KaroBio AB, and the European Union Center of Excellence Network CASCADE.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Margaret Warner for her advice and critical comments on the manuscript.

References

- Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. *Cancer Res* 1988; 48:246-53.
- MacGregor JJ, Jordan VC. Basic guide to the mechanisms of antiestrogen action. *Pharmacol Rev* 1998;50: 151-96.
- Lerner LJ, Holthaus FJ, Jr., Thompson CR. A non-steroidal estrogen antagonist 1-(*p*-2-diethylaminoethoxyphenyl)-1-phenyl-2-*p*-methoxyphenyl ethanol. *Endocrinology* 1958;63:295-318.
- Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. *Endocr Rev* 2005;26:331-45.
- Fujita T, Kobayashi Y, Wada O, et al. Full activation of estrogen receptor α activation function-1 induces proliferation of breast cancer cells. *J Biol Chem* 2003; 278:26704-14.
- Helguero LA, Faulds MH, Gustafsson JA, et al. Estrogen receptors α (ER α) and β (ER β) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. *Oncogene* 2005;24: 6605-16.
- Strom A, Hartman J, Foster JS, et al. Estrogen receptor β inhibits 17 β -estradiol-stimulated proliferation of the breast cancer cell line T47D. *Proc Natl Acad Sci U S A* 2004;101:1566-71.
- Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G $_2$ cell cycle arrest. *Cancer Res* 2004;64:423-8.
- Park BW, Kim KS, Heo MK, et al. Expression of estrogen receptor- β in normal mammary and tumor tissues: is it protective in breast carcinogenesis? *Breast Cancer Res Treat* 2003;80:79-85.
- Myers E, Fleming FJ, Crotty TB, et al. Inverse relationship between ER- β and SRC-1 predicts outcome in endocrine-resistant breast cancer. *Br J Cancer* 2004; 91:1687-93.
- Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. *Ann Surg* 1972;175:409-16.
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1995;1:27-31.
- Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. *N Engl J Med* 1991;324:1-8.
- Charnock-Jones DS, Sharkey AM, Rajput-Williams J, et al. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. *Biol Reprod* 1993;48: 1120-8.
- Ruohola JK, Valve EM, Karkkainen MJ, et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. *Mol Cell Endocrinol* 1999;149: 29-40.
- Garvin S, Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer *in vivo*. *Cancer Res* 2003;63:8742-8.
- Makris A, Powles TJ, Kakolyris S, et al. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. *Cancer* 1999;85:1996-2000.
- Muller P, Kietz S, Gustafsson J, et al. The anti-estrogenic effect of all-*trans*-retinoic acid on the breast cancer cell line MCF-7 is dependent on HES-1 expression. *J Biol Chem* 2002;277:28376-9.
- Hartman J, Muller P, Foster JS, et al. HES-1 inhibits 17 β -estradiol and heregulin- β 1-mediated upregulation of E2F-1. *Oncogene* 2004;23:8826-33.
- Rocheffort H, Bardon S, Chalbos D, et al. Steroidal and nonsteroidal antiestrogens in breast cancer cells in culture. *J Steroid Biochem* 1984;20:105-10.
- Huseby RA, Maloney TM, McGrath CM. Evidence for a direct growth-stimulating effect of estradiol on human MCF-7 cells *in vivo*. *Cancer Res* 1984;44: 2654-9.
- Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med* 2003;9:669-76.
- Chang JT, Chen IH, Liao CT, et al. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. *Clin Biochem* 2002;35: 591-6.
- Yeo KT, Wang HH, Nagy JA, et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. *Cancer Res* 1993;53:2912-8.
- Harari EF, Maretzek AF, Goldberg I, et al. Tamoxifen enhances cell death in implanted MCF7 breast cancer

- by inhibiting endothelium growth. *Cancer Res* 1994;54:5511-4.
26. Hyder SM, Nawaz Z, Chiappetta C, et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. *Cancer Res* 2000;60:3183-90.
27. Buteau-Lozano H, Ancelin M, Lardeux B, et al. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors α and β . *Cancer Res* 2002;62:4977-84.
28. Kazi AA, Jones JM, Koos RD. Chromatin immunoprecipitation analysis of gene expression in the rat uterus *in vivo*: estrogen-induced recruitment of both estrogen receptor α and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. *Mol Endocrinol* 2005;19:2006-19.
29. Weigand M, Hantel P, Kreienberg R, et al. Autocrine vascular endothelial growth factor signaling in breast cancer. Evidence from cell lines and primary breast cancer cultures *in vitro*. *Angiogenesis* 2005;8:197-204.
30. Ginsburg E, Vonderhaar BK. Stimulation of growth of human breast cancer cells (T47D) by platelet derived growth factor. *Cancer Lett* 1991;58:137-44.
31. Ryde CM, Nicholls JE, Dowsett M. Steroid and growth factor modulation of aromatase activity in MCF7 and T47D breast carcinoma cell lines. *Cancer Res* 1992;52:1411-5.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Estrogen Receptor β Inhibits Angiogenesis and Growth of T47D Breast Cancer Xenografts

Johan Hartman, Karolina Lindberg, Andrea Morani, et al.

Cancer Res 2006;66:11207-11213.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/66/23/11207>

Cited articles This article cites 31 articles, 13 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/66/23/11207.full#ref-list-1>

Citing articles This article has been cited by 15 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/66/23/11207.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/66/23/11207>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.